Human antibodies to Fel d1 and methods of use thereof

A method for desensitizing a patient who demonstrates a heightened sensitivity to, or a heightened allergic reaction against, secondary exposure to a cat, cat dander, cat hair or an extract thereof, or secondary exposure to Fel d1 protein, or for treating at least one symptom or complication associated with a heightened sensitivity to, or heightened allergic reaction against secondary exposure to a cat, cat dander, cat hair or an extract thereof, or secondary exposure to Fel d1 protein, comprising administering to a patient in need thereof an effective amount of an-isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1;

• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within an HCVR comprising the amino acid sequence of SEQ ID NO:
• 306;
• and the three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within an LCVR comprising the amino acid sequence of SEQ ID NO:
• 314 wherein the heightened sensitivity to, or a heightened allergic reaction against, secondary exposure to a cat, cat dander, cat hair or an extract thereof, or Fel d1 protein is prevented, or at least one symptom or complication associated with the heightened sensitivity to, or heightened allergic reaction against, secondary exposure to a cat, cat dander, cat hair or an extract thereof, or Fel d1 protein is prevented, following administration of the antibody or antigen-binding fragment thereof.

An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody or antigen-binding fragment thereof comprises:

• (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:
• 308;
• (b) an HCDR2 comprising the amino acid sequence of SEQ ID NO:
• 310;
• (c) an HCDR3 comprising the amino acid sequence of SEQ ID NO:
• 312;
• (d) an LCDR1 comprising the amino acid sequence of SEQ ID NO:
• 316;
• (e) an LCDR2 comprising the amino acid sequence of SEQ ID NO:
• 318;
• and
• (f) an LCDR3 comprising the amino acid sequence of SEQ ID NO:
• 320.

A pharmaceutical composition comprising a first monoclonal antibody or an antigen-binding fragment thereof that binds specifically to Fel d1 and a second monoclonal antibody or antigen binding fragment thereof that binds specifically to Fel d1,

• wherein the first antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:
• 308, an HCDR2 comprising the amino acid sequence of SEQ ID NO:
• 310, an HCDR3 comprising the amino acid sequence of SEQ ID NO:
• 312, an LCDR1 comprising the amino acid sequence of SEQ ID NO:
• 316, an LCDR2 comprising the amino acid sequence of SEQ ID NO:
• 318, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
• 320;
• and
• wherein the second antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:
• 20, an HCDR2 comprising the amino acid sequence of SEQ ID NO:
• 22, an HCDR3 comprising the amino acid sequence of SEQ ID NO:
• 24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:
• 28, an LCDR2 comprising the amino acid sequence of SEQ ID NO:
• 30, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
• 32.